Neurological soft signs and subcortical brain morphology in recent onset schizophrenia

Journal of Psychiatric Research

Volumn 46, Issue 4, 2012, Pages 533-539

  Hirjak, Dusan ^a   Wolf, Robert C ^a   Stieltjes, Bram ^b   Seidl, Ulrich ^c   Schröder, Johannes ^a   Thomann, Philipp A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c KLINIKUM STUTTGART   (Germany)

Author keywords

Basal ganglia; Magnetic resonance imaging; Neurological soft signs; Schizophrenia; Thalamus

Indexed keywords

ADULT; ARTICLE; CAUDATE NUCLEUS; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; GLOBUS PALLIDUS; HUMAN; MALE; MORPHOLOGY; NEUROLOGIC DISEASE; NEUROLOGICAL SOFT SIGN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PUTAMEN; REMISSION; SCHIZOPHRENIA; THALAMUS;

EID: 84858295286     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.01.015     Document Type: Article

References (53)

1. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1983, University of Iowa, Iowa City, Iowa.
2. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City, Iowa.
3. Andreasen N.C., Nopoulos P., O'Leary D.S., Miller D.D., Wassink T., Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biological Psychiatry 1999, 46:908-920.
4. Bachmann S., Bottmer C., Schroder J. Neurological soft signs in first-episode schizophrenia: a follow-up study. American Journal of Psychiatry 2005, 162:2337-2343.
5. Ballmaier M., Schlagenhauf F., Toga A.W., Gallinat J., Koslowski M., Zoli M., et al. Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophrenia Research 2008, 106:140-147.
6. Bogerts B., Falkai P., Haupts M., Greve B., Ernst S., Tapernon-Franz U., et al. Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Initial results from a new brain collection. Schizophrenia Research 1990, 3:295-301.
7. Bogerts B., Meertz E., Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Archives of General Psychiatry 1985, 42:784-791.
8. Buchsbaum M.S., Shihabuddin L., Brickman A.M., Miozzo R., Prikryl R., Shaw R., et al. Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophrenia Research 2003, 64:53-62.
9. Byne W., Buchsbaum M.S., Mattiace L.A., Hazlett E.A., Kemether E., Elhakem S.L., et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. American Journal of Psychiatry 2002, 159:59-65.
10. Byne W., Kidkardnee S., Tatusov A., Yiannoulos G., Buchsbaum M.S., Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophrenia Research 2006, 85:245-253.
11. Chakravarthy V.S., Joseph D., Bapi R.S. What do the basal ganglia do? A modeling perspective. Biological Cybernetics 2010, 103:237-253.
12. Chan R.C., Gottesman I.I. Neurological soft signs as candidate endophenotypes for schizophrenia: a shooting star or a northern star?. Neuroscience and Biobehavioral Reviews 2008, 32:957-971.
13. Chan R.C., Xu T., Heinrichs R.W., Yu Y., Gong Q.Y. Neurological soft signs in non-psychotic first-degree relatives of patients with schizophrenia: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 2010, 34:889-896.
14. Chen Y.L., Chen Y.H., Mak F.L. Soft neurological signs in schizophrenic patients and their nonpsychotic siblings. Journal of Nervous and Mental Disease 2000, 188:84-89.
15. Corson P.W., Nopoulos P., Andreasen N.C., Heckel D., Arndt S. Caudate size in first-episode neuroleptic-naive schizophrenic patients measured using an artificial neural network. Biological Psychiatry 1999, 46:712-720.
16. Csernansky J.G., Schindler M.K., Splinter N.R., Wang L., Gado M., Selemon L.D., et al. Abnormalities of thalamic volume and shape in schizophrenia. American Journal of Psychiatry 2004, 161:896-902.
17. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005, 30:765-774.
18. Dazzan P., Morgan K.D., Orr K.G., Hutchinson G., Chitnis X., Suckling J., et al. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain 2004, 127:143-153.
19. Ebdrup B.H., Skimminge A., Rasmussen H., Aggernaes B., Oranje B., Lublin H., et al. Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. International Journal of Neuropsychopharmacology 2011, 14:69-82.
20. Glenthoj A., Glenthoj B.Y., Mackeprang T., Pagsberg A.K., Hemmingsen R.P., Jernigan T.L., et al. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Research 2007, 154:199-208.
21. Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., Gur R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. American Journal of Psychiatry 1998, 155:1711-1717.
22. Harms M.P., Wang L., Mamah D., Barch D.M., Thompson P.A., Csernansky J.G. Thalamic shape abnormalities in individuals with schizophrenia and their nonpsychotic siblings. Journal of Neuroscience 2007, 27:13835-13842.
23. Heinrichs D.W., Buchanan R.W. Significance and meaning of neurological signs in schizophrenia. American Journal of Psychiatry 1988, 145:11-18.
24. Heuser M., Thomann P.A., Essig M., Bachmann S., Schroder J. Neurological signs and morphological cerebral changes in schizophrenia: an analysis of NSS subscales in patients with first episode psychosis. Psychiatry Research 2011, 192:69-76.
25. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. American Journal of Psychiatry 2005, 162:2233-2245.
26. Jahn T., Hubmann W., Karr M., Mohr F., Schlenker R., Heidenreich T., et al. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses. Psychiatry Research 2006, 142:191-199.
27. Janssen J., Diaz-Caneja A., Reig S., Bombin I., Mayoral M., Parellada M., et al. Brain morphology and neurological soft signs in adolescents with first-episode psychosis. British Journal of Psychiatry 2009, 195:227-233.
28. Jayakumar P.N., Venkatasubramanian G., Gangadhar B.N., Janakiramaiah N., Keshavan M.S. Optimized voxel-based morphometry of gray matter volume in first-episode, antipsychotic-naive schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 2005, 29:587-591.
29. Keshavan M.S., Rosenberg D., Sweeney J.A., Pettegrew J.W. Decreased caudate volume in neuroleptic-naive psychotic patients. American Journal of Psychiatry 1998, 155:774-778.
30. Khorram B., Lang D.J., Kopala L.C., Vandorpe R.A., Rui Q., Goghari V.M., et al. Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine. American Journal of Psychiatry 2006, 163:2005-2007.
31. Konick L.C., Friedman L. Meta-analysis of thalamic size in schizophrenia. Biological Psychiatry 2001, 49:28-38.
32. Lang D.J., Kopala L.C., Vandorpe R.A., Rui Q., Smith G.N., Goghari V.M., et al. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. American Journal of Psychiatry 2001, 158:625-631.
33. Mamah D., Harms M.P., Wang L., Barch D., Thompson P., Kim J., et al. Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients. Biological Psychiatry 2008, 64:111-120.
34. Mamah D., Wang L., Barch D., de Erausquin G.A., Gado M., Csernansky J.G. Structural analysis of the basal ganglia in schizophrenia. Schizophrenia Research 2007, 89:59-71.
35. Massana G., Salgado-Pineda P., Junque C., Perez M., Baeza I., Pons A., et al. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. Journal of Clinical Psychopharmacology 2005, 25:111-117.
36. Mouchet-Mages S., Canceil O., Willard D., Krebs M.O., Cachia A., Martinot J.L., et al. Sensory dysfunction is correlated to cerebellar volume reduction in early schizophrenia. Schizophrenia Research 2007, 91:266-269.
37. Mouchet-Mages S., Rodrigo S., Cachia A., Mouaffak F., Olie J.P., Meder J.F., et al. Correlations of cerebello-thalamo-prefrontal structure and neurological soft signs in patients with first-episode psychosis. Acta Psychiatrica Scandinavica 2011, 123:451-458.
38. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 2009, 39:1763-1777.
39. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
40. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychological Reports 1962, 10:799-812.
41. Patenaude B., Smith S.M., Kennedy D.N., Jenkinson M.A. Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011, 56:907-922.
42. Qiu A., Zhong J., Graham S., Chia M.Y., Sim K. Combined analyses of thalamic volume, shape and white matter integrity in first-episode schizophrenia. Neuroimage 2009, 47:1163-1171.
43. Scherk H., Falkai P. Effects of antipsychotics on brain structure. Current Opinion in Psychiatry 2006, 19:145-150.
44. Schroder J., Niethammer R., Geider F.J., Reitz C., Binkert M., Jauss M., et al. Neurological soft signs in schizophrenia. Schizophrenia Research 1991, 6:25-30.
45. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophrenia Research 2001, 49:1-52.
46. Smieskova R., Fusar-Poli P., Allen P., Bendfeldt K., Stieglitz R.D., Drewe J., et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia? - a systematic review. Current Pharmaceutical Design 2009, 15:2535-2549.
47. Strauss J.S., Carpenter W.T. The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. Archives of General Psychiatry 1974, 31:37-42.
48. Strungas S., Christensen J.D., Holcomb J.M., Garver D.L. State-related thalamic changes during antipsychotic treatment in schizophrenia: preliminary observations. Psychiatry Research 2003, 124:121-124.
49. Thomann P.A., Wustenberg T., Santos V.D., Bachmann S., Essig M., Schroder J. Neurological soft signs and brain morphology in first-episode schizophrenia. Psychological Medicine 2009, 39:371-379.
50. Venkatasubramanian G., Jayakumar P.N., Gangadhar B.N., Keshavan M.S. Neuroanatomical correlates of neurological soft signs in antipsychotic-naive schizophrenia. Psychiatry Research 2008, 164:215-222.
51. Wittchen H.U., Wunderlich U., Gruschwitz S., Zaudig M. SKID-I: Strukturiertes klinisches Interview für DSM-IV 1997, Hogrefe, Göttingen.
52. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 2003, 64:663-667.
53. Young K.A., Manaye K.F., Liang C., Hicks P.B., German D.C. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biological Psychiatry 2000, 47:944-953.